Dorubin Injection 20 mg/4 ml contains Daunorubicin, an anthracycline antibiotic widely used in chemotherapy for the treatment of hematologic malignancies and certain solid tumors. Daunorubicin exerts its anticancer effect by intercalating DNA strands and inhibiting topoisomerase II, thereby preventing DNA replication and RNA synthesis in rapidly dividing cells. This leads to the selective death of cancerous cells while sparing most normal tissues.

Dorubin is an essential component of combination chemotherapy regimens, often used alongside cytarabine and other chemotherapeutic agents to enhance efficacy in treating leukemia and lymphoma. Its intravenous formulation ensures precise dosing, rapid systemic distribution, and reliable absorption for optimal therapeutic effect.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Dorubin Injection 20 mg/4 ml is indicated for:

• Acute myeloid leukemia (AML) in adults and pediatric patients, as part of induction or consolidation therapy

• Acute lymphoblastic leukemia (ALL) in combination regimens

• Chronic myeloid leukemia (CML) blast crisis

• Other hematologic malignancies as determined by an oncologist

• Occasionally used in solid tumors within specific combination chemotherapy protocols

Dorubin is particularly valuable in patients who require aggressive cytotoxic therapy for rapidly progressing cancers.

Dosage and Administration

• Route: Intravenous infusion only. Dorubin must never be administered intramuscularly or subcutaneously due to the risk of severe tissue necrosis (extravasation).

• Adult dosage: Typically calculated based on body surface area (mg/m²), administered in cycles as per specific chemotherapy protocols.

• Pediatric dosage: Carefully calculated according to body surface area, age, and clinical condition under strict supervision.

• Infusions are usually administered over 5–15 minutes, with close monitoring for adverse reactions.

Dosage adjustments are essential for patients with hepatic impairment or previous cumulative anthracycline exposure due to the risk of cardiotoxicity. Lifelong cumulative dosing limits should be observed.

Precautions

• Dorubin is a highly cytotoxic chemotherapeutic agent and should only be administered by trained healthcare professionals in a controlled clinical setting.

• Cardiac monitoring is required before and during therapy due to the risk of cardiomyopathy and heart failure.

• Use caution in patients with liver or kidney dysfunction, bone marrow suppression, or active infections.

• Pregnancy and breastfeeding are contraindicated; Daunorubicin is teratogenic.

• Avoid concomitant use with other cardiotoxic agents unless medically necessary and monitored.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects of Dorubin Injection include:

• Myelosuppression: leukopenia, neutropenia, anemia, thrombocytopenia

• Gastrointestinal effects: nausea, vomiting, mucositis, diarrhea

• Hair loss (alopecia)

• Red discoloration of urine for 1–2 days post-injection (harmless)

Serious but rare adverse effects include:

• Cardiotoxicity: arrhythmias, congestive heart failure, cardiomyopathy

• Severe infections due to immunosuppression

• Extravasation injury at the injection site leading to tissue necrosis

Frequent monitoring of blood counts, liver function, and cardiac status is essential to manage toxicity.

Storage

Store at 2–8°C, protect from light, and do not freeze. Keep out of reach of children. Use only under professional supervision.

Dorubin Injection 20 mg/4 ml is a highly effective chemotherapeutic agent for treating leukemia and other hematologic malignancies. Its potent anticancer activity, when combined with careful monitoring and adherence to chemotherapy protocols, helps improve patient survival and disease management outcomes.